High-dose cyclophosphamide in small-cell carcinoma of the lung. 1985

R L Souhami, and G Finn, and W M Gregory, and B G Birkhead, and R Buckman, and D Edwards, and A H Goldstone, and P G Harper, and S G Spiro, and J S Tobias

Eighteen patients with untreated small-cell cancer of the lung have been treated with cyclophosphamide 200 mg/kg on two occasions at an interval of four weeks. An additional eight patients received etoposide in addition to cyclophosphamide. Measurements of tumor volume were made by thoracic computed tomographic (CT) scan before and after each cycle. When compared with our previous study in which only one cycle of cyclophosphamide was given, the double procedure did not increase response rate, decrease the incidence of local relapse, or prolong the relapse-free interval. Survival after relapse was shorter with two cycles of chemotherapy mainly due to greater difficulty in administering further chemotherapy. The CT scans showed a decrease in tumor volume from 99.2 cc to 21 cc after the first cycle, but a smaller decrease to 14.1 cc after the second. These results show that the rapid emergence of drug resistance imposes limitations on the use of very high-dose cytotoxic chemotherapy.

UI MeSH Term Description Entries
D008175 Lung Neoplasms Tumors or cancer of the LUNG. Cancer of Lung,Lung Cancer,Pulmonary Cancer,Pulmonary Neoplasms,Cancer of the Lung,Neoplasms, Lung,Neoplasms, Pulmonary,Cancer, Lung,Cancer, Pulmonary,Cancers, Lung,Cancers, Pulmonary,Lung Cancers,Lung Neoplasm,Neoplasm, Lung,Neoplasm, Pulmonary,Pulmonary Cancers,Pulmonary Neoplasm
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D003520 Cyclophosphamide Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. (+,-)-2-(bis(2-Chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-Oxide Monohydrate,B-518,Cyclophosphamide Anhydrous,Cyclophosphamide Monohydrate,Cyclophosphamide, (R)-Isomer,Cyclophosphamide, (S)-Isomer,Cyclophosphane,Cytophosphan,Cytophosphane,Cytoxan,Endoxan,NSC-26271,Neosar,Procytox,Sendoxan,B 518,B518,NSC 26271,NSC26271
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D013997 Time Factors Elements of limited time intervals, contributing to particular results or situations. Time Series,Factor, Time,Time Factor

Related Publications

R L Souhami, and G Finn, and W M Gregory, and B G Birkhead, and R Buckman, and D Edwards, and A H Goldstone, and P G Harper, and S G Spiro, and J S Tobias
March 1978, Cancer treatment reports,
R L Souhami, and G Finn, and W M Gregory, and B G Birkhead, and R Buckman, and D Edwards, and A H Goldstone, and P G Harper, and S G Spiro, and J S Tobias
January 1985, Cancer,
R L Souhami, and G Finn, and W M Gregory, and B G Birkhead, and R Buckman, and D Edwards, and A H Goldstone, and P G Harper, and S G Spiro, and J S Tobias
January 1985, Cancer chemotherapy and pharmacology,
R L Souhami, and G Finn, and W M Gregory, and B G Birkhead, and R Buckman, and D Edwards, and A H Goldstone, and P G Harper, and S G Spiro, and J S Tobias
January 1985, Cancer chemotherapy and pharmacology,
R L Souhami, and G Finn, and W M Gregory, and B G Birkhead, and R Buckman, and D Edwards, and A H Goldstone, and P G Harper, and S G Spiro, and J S Tobias
January 1983, Cancer chemotherapy and pharmacology,
R L Souhami, and G Finn, and W M Gregory, and B G Birkhead, and R Buckman, and D Edwards, and A H Goldstone, and P G Harper, and S G Spiro, and J S Tobias
February 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
R L Souhami, and G Finn, and W M Gregory, and B G Birkhead, and R Buckman, and D Edwards, and A H Goldstone, and P G Harper, and S G Spiro, and J S Tobias
February 1994, Seminars in oncology,
R L Souhami, and G Finn, and W M Gregory, and B G Birkhead, and R Buckman, and D Edwards, and A H Goldstone, and P G Harper, and S G Spiro, and J S Tobias
January 1982, Cancer chemotherapy and pharmacology,
R L Souhami, and G Finn, and W M Gregory, and B G Birkhead, and R Buckman, and D Edwards, and A H Goldstone, and P G Harper, and S G Spiro, and J S Tobias
March 1986, Journal of the National Medical Association,
R L Souhami, and G Finn, and W M Gregory, and B G Birkhead, and R Buckman, and D Edwards, and A H Goldstone, and P G Harper, and S G Spiro, and J S Tobias
September 2001, Bulletin du cancer,
Copied contents to your clipboard!